Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The price movement in this stock sure justifies the 1.45 beta. High volatility, but nice overall trend. Big price swings.
Encouraging, like to see some of this optimism transition into the stock price. Holding for over a year now, hoping this continues to proceed to investment status instead of the lotto category. Phase I results early next year will definitely be a price mover. Thanks for the update.
'To say that Square's third-quarter results were impressive would be a massive understatement. Total net revenue grew by a staggering 140% year-over-year to more than $3 billion.'
I think those two sentences sums up the quarterly performance perfectly. Also like the comment: ". . . not only that, but Square is growing in ways that should produce durable and growing revenue streams for years to come."
Was tempted to write $185 calls prior to ER due to PayPal's 3rd qtr debacle, fortunately I decided to stay put since I continue to want to be a shareholder in this company's future. Thanks for posting the recap.
What a fabulous move this week!! Thought we would have had some difficulty breaking $117.75, but turns out we just ripped through it with volume. ATH for the stock.
Good support in high $70's low $80's, very favorable risk reward situation. Long term, stock is very promising fundamentally. Big Fortune 500 companies being signed every quarter. New product to be launched. Technically, gap around $109 should provide a bullish move as we draw closer. Sold multiple $82 puts, this feels likes it wants to go higher now.
Yes, nicely with heavier volume as well. Wouldn't mind it trading sideways for a week, it has been nonstop up and gaining momentum since the March lows. Incredible.
Stock has been very strong since the March lows. Comparing it to SHOP, looks like ETSY has room to continue its run; assuming market does not correct. SHOP is egregiously valued since the start of this run, but the high Growth Rate the past 5 years argues for a higher valuation over its competitiors. ETSY seems like a solid buy and the `less' risky participant in this sector.
ETSY
Mkt Cap 12.45B
Sales 877 B
Bk shr 3.44
Cash shr 6.86
PE 180
PEG 4.52
Price/Sh 14.20
Price/Bk 30.88
5 yr sales 33.1%
SHOP
Mkt Cap 112.0B
Sales 1.73B
Bk shr 26.03
Cash shr 20.00
PE -
PEG -
Price/Sh 64.85
Price/Bk 36.47
5 yr sales 71.9%
Company managed to successfully convince one of the large investors to change their nay vote. All items passed with the exception of the issuance of additional shares. Apparently the concession for changing their vote was to make the point the company must produce before they get access to any additional funds. No more dilutive financing without results. Minor victory, but largely disappointed.
It appears that the Company does not have the shareholder votes to re-elect the Board of Directors nor approve the ridiculous compensation management is getting. We will know tomorrow (if not postponed). I hope all proposals fail. Cooper is not CEO material, not even senior manager level of any kind. Never invest in a biotech with an MD at the helm, never; no matter how promising. So many clinical deadlines have passed, so many promises broken, no urgency to get things done; no fiduciary sense of any kind, no shareholder accountability. All this without a modicum of explanation of any kind to the shareholders. The ridiculous secondary of four months ago was the last straw, literally conceding to shorts by allowing them to `invest' and cover. . . . the same people who have tried to bankrupt this company for the last five years.
The company may take a $$ hit on this but will ultimately be placed in more competent hands; we can not get any worse decision making than present. We have no idea after five years of what, if any, of this `ground breaking' technology clinically works. Clearly there are issues with the NCI. Programs invested in five years ago just drop off the company radar with no comment by management. Worst company I have ever encountered. Millions of bonuses and compensation to Cooper over the years and he has not once bought a single share in this company; just the recipient of endless gifts. Complete disgrace. Don't want him as CMO either. Carl June to the rescue please.
Looks like a deal with MD Anderson. Has to help company clinical credibility immensely.
https://www.bizjournals.com/austin/news/2020/05/08/genprex-strikes-deal-with-md-anderson-cancer.html
Overall, solid report. Delayed implementation is unfortunate, but certainly understandable. Looks like we are going to give back our entire price pop to $14.71 before day is over. Believe we are considerably higher by year end. Mid-year 2021 will be the real gauge as to the rate of adaptation and acceptance of the Tulsa system.
I thought I read that Beaumont Hospital(s) (the largest or second largest healthcare system in Michigan) provides Tulsa-Pro procedures, but am unable to find it now to post. Solid report, encouraging progress, buying more shares end of day.
Clearly Cooper deserves another bonus, talent like his is hard to come by.
5 years as CEO - nothing accomplished/achieved. Everything delayed yet again; this time, saved by the virus. First three years was the conflict with Kirk. First dosing of a patient rumored to be any decade now.
Just one shot left on goal now from three decent shots outlined five years ago. Any hope now is placed solely on Rosenberg. No longer an investment, merely one roll of the roulette ball. Technology of numerous other biotechs have caught and surpassed us, this is merely a management ATM. Cooper has not bought one share in this company from his own funds.
I also remember Israeli scientists proclaimed a breakthrough for a cancer cure last year as well. Any vaccine research/experience will be helpful for the next viral crisis, but this one will have run its course by the time a vaccine is ready in necessary quantity. However, feel this current outbreak is far from over, and there will be many more sensationalized headlines to come so the investment banker algos can continue to pillage retail; thereby offsetting some of their bonus options share price loses.
Ladenburg Thalmann Financial Services is a German Company who posted the $290 target. Way to rich in my opinion; need the revenue stream first. Happy to see it though, I am holding.
Currently $32M in sales, $7.5B Market cap, 230 Price to Sales. It certainly has high hopes the two NDAs will be successful and prompt commercial roll-out possible.
Saw this on another board, do not recognize the company. Also do not see this price target listed/updated yet from firms covering this stock.
Laden $RETA: Two NDA Filings, BARD and OMAV, Expected in 2020; Buy and Raise PT to $290
Earnings out and are favorable. Management guides revenues a bit higher. Great stock to have been in the last two years. Waiting for conference call notes.
https://markets.businessinsider.com/news/stocks/shopify-guides-fy20-revenues-above-estimates-quick-facts-1028897901
Secondary - 2.1M shares @ $4
https://newsfilter.io/a/7daf655cf66c24a2f6fef7ce63b85019
Not a terrible first day for a new secondary issuance; stock recovered almost 50% from a 9% sell off in pre-market. I want to learn more about the quality/reputation of the acquirers. If the likes of Wainwright or other hatchet shops are involved, we all know how this will turn out. Prefer buying at support sub $4, but a temp floor may now be in. We'll see.
Good move, keep watching. $2's are very possible. Another secondary to dilute shareholders. No progress in last five years. Clinical trial pulled with no management comment. Secondary issued with no management comments. Only one remaining "shot" on goal. Rosenberg NCI trial has still not dosed its first patient. IL-12 looks like a bust after being a primary strategy for years. Other Bio companies making great strides; our heralded Sleeping Beauty delivery system on the verge of being completely antiquated as CEO bumbles around letting timeline after timeline slip. Terrible CEO and probably not CMO caliber either (despite being a self proclaimed genius). Lawrence had MDA roots, I bet they do not miss him.
Still hope for share price improvement of course, but buying it as a lottery ticket should be your financial objective. PROF and AUPH are just two of dozens of better investments if you are looking for clinical stage or recently FDA approved companies. Was a bull on this company for years, now just a bag holder on my remaining few shares.
I'm showing earnings est of 0.24 with a release date of Feb 12 after market close. Enjoying this run into earnings. Market has been incredible.
Great chart, upper end of fairly valued. Coronavirus may create a good entry point if containment can be reasonably assured in the next week. PEG ratio of 2.36 is high, but earnings forecasts one year out brings the PE to a much more reasonable 26. Of course, all contingent on how much damage the current epidemic unleashes.
If the stock can regain its footing, seems like it has the ability to deliver solid performance this year.
Phase 3 Cardinal Successful Outcome
Company announces Ph 3 results. Sucessfull endpoints achieved.
https://www.investors.com/news/technology/reata-stock-tumbles-despite-positive-results-kidney-disease-test/
Per Marketbeat.com
Cohu, Inc. (NASDAQ:COHU) posted its quarterly earnings data on Monday, August, 5th. The semiconductor company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.06. The semiconductor company had revenue of $150.01 million for the quarter, compared to analyst estimates of $152.50 million. Cohu had a positive return on equity of 1.47% and a negative net margin of 16.93%. The company's quarterly revenue was up 50.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.64 earnings per share.
4 brokers have issued 12 month price targets for Cohu's shares. Their predictions range from $20.00 to $28.00. On average, they anticipate Cohu's share price to reach $23.50 in the next year. This suggests a possible upside of 64.7% from the stock's current price.
That is a significant announcement for ZIOP. Great NIH and MDA connections should give our minimal company some bandwidth as future development and clinical trials start. Plus, like the idea that such a renowned researcher accepts our clinical approach.
Closed above 200 DMA on increased volume. Historically, not a strong indicator, but who knows if this time it will be different.
Glad that qtr is behind us, absolutely horrendous three months. Guidance is up for remainder of 2019, but from these levels, it sure has to be, no where else to go. Lets see how today's pre-market gains perform today. Will sell some putts after today. Not adding to existing holdings yet. What is painfully obvious to me today is what a major impact crypto had on previous performance . . . despite management downplaying its role. Gaming sector absolutely sucked. Data Center revenues also hit the skids, big disappointment for me. Not clear on inventory of gaming cards that will need deep discount to move off of warehouse shelves. Still positive on company; next qtr will tell us what progress we are/are not making from this new inflection point.
Yes, any potential progress will come from Precigen, ZIOP is circling the drain; nothing but baseless promises and zero execution. Totally unqualified CEO (learn on the go), no staff or adequate financial resources, competition could care less about Sleeping Beauty. I violated my own biotech rule; never invest when the Chief Medical Officer is in a CEO role. Pathetic execution, nothing more than a "hope and a prayer" gamble now for b/e.
Holding, or God forbid, extending these morning gains would be a start to recovery. All indicies, however, seems like they have no interest in complying. Even sector specific XLK is flat with a continued dubious outlook. Don't think we are out of the woods until we close and stay above $180; but unfortunately not seeing how we get there anytime soon. Market continues to tie us to the crypto wagon, convenient excuse for them to punish us with their algos. As dramatic as the drop has been, no confirmed market capitulation yet, more damage to be done. We are transforming into a value stock at this rate. Preparing for more backfill in the near future. Tough market but trying to stay objective and ready.
Nice turn around in the indices yesterday. Light job reports received favorably by the street this morning since it is seen as lowering the inflation rate rise risk. Dow futures went from red to green upon release. Are we out of the woods or just a setup for another head fake? Selling $165 putts for nice $10 premiums. Would not mind filling out my position for $155 long term if put to me.
NVDA reporting this afternoon.
Good luck everyone. This afternoon's ER will most likely cause significant swings. I'm in for the long run, so I am holding, just not playing earnings option this time. Earnings most likely will be solid. The "spin" created to justify the negative high speed algorithm trading will be the issue. Regardless, next three months we certainly should be higher. Who knows, maybe Jensen will have a surprise announcement to offset things.
SQ beats on top and bottom lines and is getting hammered. NVDA reports 11/15. Expect no different. Very unsettled market plays into the hands of investment banks and high speed algorithms feasting on their self induced market volitility.
AAPL beat estimates but guiding cautiously for upcoming quarter. More bumps in the road ahead for tech. That is both AMZN and AAPL that have been taken to the woodshed; almost a can't win scenario this earnings season. Feel certain NVDA will beat estimates, but algos will be set to take it down for any given reason. Need some positive news on the Turing chip or data center revenues to stem the tide. Think we are fine long term, but short term market concerns and the upcoming election could smack us down once again.
After yesterday's major hit, was hoping the upbeat futures this morning would get us a quarter of our losses back; instead we are down significantly yet again in pre-market. Though no specific NVDA news, industry related headlines include: AMD earnings miss, Death Cross for semiconductor industry, Texas Instr says demand is slowing, NASDAQ crash prediction . . . among a host of similar headlines.
Hopefully the worst will be over soon, but it looks still premature to be buying additional shares at this point. Hopefully $180 will be the absolute line in the sand, it looks to be a very strong support base. Good call Danny on your $200 target, I was hoping $235 was going to hold at the time. Though this has been extremely painful, I am holding and will hopefully be buying once a bottom is established. We need the general market to stabilize first; a continued downtrend will be ruinous. TSLA earnings helped, we need other big boys to step it up as well. AMZN will be critical tonight. Good luck all.
Great move today as a result of a new $400 price target. Well deserved after a month of limited traction. Nice fat option premiums, been selling $267.50 putts for last couple weeks. Next earnings report 11/08/18 +/- a day or so.
"After hosting investor meetings with Nvidia management, Evercore ISI analyst C.J. Muse said he believes investors are now more appreciative of Nvidia's opportunity in creating the AI industry standard and the company's "positive feedback loop" within deep learning. Longer-term, he sees tremendous growth opportunities led by the new Turing architecture, which further entrenches Nvidia's high-end gaming moat and presents a "meaningful" opportunity in Inference, Muse tells investors. The analyst, who sees Nvidia being poised to grow EPS at a 30-35% CAGR through 2020 and beyond, raised his price target on the stock to $400 from $300 and keeps an Outperform rating on the shares "
Priority Review Vouchers
https://priorityreviewvoucher.org/
Eligibility
To be eligible for a PRV, the drug or vaccine must satisfy the following criteria.
Treat one of the following diseases:
Blinding trachoma
Buruli Ulcer
Chagas (FDA added in 2015)
Chikungunya virus disease (FDA added in 2018)
Cholera
Cryptococcal meningitis (FDA added in 2018)
Dengue
Dracunculiasis
Fascioliasis
Filoviruses (including Ebola) (Congress added in 2014)
Human African trypanosomiasis
Lassa fever (FDA added in 2018)
Leishmaniasis
Leprosy
Lymphatic filariasis
Malaria
Material threat medical countermeasures (Congress added in 2016)
Neurocysticercosis (FDA added in 2015)
Onchocerciasis
Rabies (FDA added in 2018)
Rare pediatric disease (Congress added in 2012)
Schistosomiasis
Soil transmitted helminthiasis
Tuberculosis
Yaws
Zika (Congress added in 2016)
Contain no active ingredient (including any ester or salt of the active ingredient) that has been approved in any other FDA application.
Offer major advances in treatment, or provide treatment where no adequate therapy exists, thus earning priority review on its own merit. In other words, to win a bonus priority review, the treatment must first get its own priority review.
See "Extension to Rare Pediatric" below for eligibility for a pediatric vouchers.
Recipients
The table below includes both the recipient of the voucher and the user of the voucher.
Year Disease Drug Company Price User Drug
1. 2009 Malaria Coartem (artemether/lumefantrine) Novartis Retained Novartis Ilaris (canakinumab)
2. 2012 Tuberculosis Sirturo (bedaquiline) Janssen (JNJ) Retained Janssen (JNJ) Tremfya (guselkumab)
3. 2014 Morquio A syndrome Vimizim (elosulfase alfa) BioMarin $67.5 million Regeneron/Sanofi Praluent (alirocumab)
4. 2014 Leishmaniasis Impavido (miltefosine) Knight $125 million Gilead Odefsey
5. 2015 High-risk neuroblastoma Unituxin (dinutuximab) United Therapeutics $350 million AbbVie
6. 2015 Rare bile acid synthesis disorders Cholbam (cholic acid) Asklepion $245 million Sanofi Combo diabetes
7. 2015 Hereditary orotic aciduria Xuriden (uridine triacetate) Wellstat Sold AstraZeneca
8. 2015 Hypophosphatasia Alexion *
9. 2015 Lysosomal acid lipase (LAL) deficiency Kanuma (sebelipase alfa) Alexion *
10. 2016 Cholera Vaxchora PaxVax *
11. 2016 Duchenne muscular dystrophy Exondys 51 (eteplirsen) Sarepta $125 million Gilead Combo HIV
12. 2016 Spinal muscular atrophy (SMA) Spinraza (nusinersen) Biogen *
13. 2017 Duchenne muscular dystrophy Emflaza (deflazacort) Marathon *
14. 2017 Batten disease Brineura (cerliponase alfa) BioMarin $125 million
15. 2017 Chagas Benznidazole Chemo Research
16. 2017 B-cell acute lymphoblastic leukemia Tisagenlecleucel Novartis
17. 2017 Mucopolysaccharidosis (MPS) VII Mepsevii Ultragenyx $130 million Novartis
18. 2017 Biallelic RPE65 mutation-associated retinal dystrophy Luxturna (voretigene neparvovec-rzyl) Spark $110 million Jazz
19. 2018 X-linked hypophosphatemia (XLH) Crysvita (burosumab-twza) Ultragenyx $80.6 million
20. 2018 Onchocerciasis (river blindness) Moxidectin Medicines Development
21. 2018 Lennox-Gastaut or Dravet syndromes Epidiolex (cannabidiol) GW Research
22. 2018 Smallpox TPOXX (tecovirimat) SIGA
23. 2018 Malaria Krintafel (tafenoquine) GSK and MMV
* Anonymous companies have sold several vouchers, including one sold to ViiV for $130 MM and another to Teva for $150MM in 2017.
Bottom looks to be in from a TA perspective, good risk/reward starting point. Fundamentally, news and progress will eventually support/mitigate current share price. Cohart 5 results released last week or so is a good start and recent presentation at 8/29 biotech conference helps as well. Filling the TA gap is also very enticing. In with a new position.
Much needed bounce off the 200 dma this morning. Will it hold up?? Fundamentally, good earnings report last quarter with achievable growth targets for upcoming quarter. Remain optimistic long term.
Oppenheimer upgrades to Outperform
Action Action Current PT
8/17/18 Oppenheimer Upgrades Outperform 0.0
8/17/18 Stifel Nicolaus Maintains Hold 250.0
8/15/18 Wells Fargo Upgrades Outperform 315.0
Oppenheimer Price target $310 per different article.
https://www.benzinga.com/stock/nvda/ratings